Abdelrahman Fouda
Concepts (199)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Reperfusion Injury | 7 | 2023 | 118 | 3.130 |
Why?
| Arginase | 10 | 2023 | 39 | 3.050 |
Why?
| Retina | 6 | 2024 | 64 | 2.540 |
Why?
| Retinal Diseases | 4 | 2024 | 49 | 2.450 |
Why?
| Neuroprotective Agents | 5 | 2021 | 125 | 2.130 |
Why?
| Stroke | 10 | 2022 | 526 | 1.930 |
Why?
| Receptor, Angiotensin, Type 2 | 4 | 2022 | 25 | 1.740 |
Why?
| Retinal Neovascularization | 2 | 2022 | 5 | 1.560 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 4 | 2019 | 46 | 1.390 |
Why?
| Renin-Angiotensin System | 3 | 2019 | 64 | 1.370 |
Why?
| Thiophenes | 5 | 2022 | 37 | 1.170 |
Why?
| Brain | 7 | 2021 | 1387 | 1.090 |
Why?
| Diabetic Retinopathy | 2 | 2024 | 41 | 1.090 |
Why?
| Macrophages | 5 | 2024 | 405 | 1.080 |
Why?
| Sulfonamides | 5 | 2022 | 146 | 1.070 |
Why?
| Ischemia | 3 | 2024 | 177 | 1.050 |
Why?
| Infarction, Middle Cerebral Artery | 6 | 2022 | 44 | 1.020 |
Why?
| Retinopathy of Prematurity | 1 | 2022 | 17 | 0.870 |
Why?
| Animals | 28 | 2023 | 14385 | 0.870 |
Why?
| Minocycline | 2 | 2017 | 18 | 0.760 |
Why?
| Luminescent Agents | 1 | 2020 | 5 | 0.750 |
Why?
| Retinal Vessels | 1 | 2020 | 13 | 0.740 |
Why?
| Muramidase | 1 | 2020 | 17 | 0.740 |
Why?
| Integrases | 1 | 2020 | 45 | 0.740 |
Why?
| Luminescent Proteins | 1 | 2020 | 66 | 0.730 |
Why?
| Brain Injuries | 1 | 2021 | 183 | 0.720 |
Why?
| Skin Aging | 1 | 2019 | 15 | 0.720 |
Why?
| Cadherins | 1 | 2020 | 72 | 0.710 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 82 | 0.710 |
Why?
| Endothelins | 1 | 2019 | 19 | 0.700 |
Why?
| Disease Models, Animal | 13 | 2023 | 1639 | 0.700 |
Why?
| Angiogenesis Inducing Agents | 2 | 2016 | 8 | 0.690 |
Why?
| Antigens, CD | 1 | 2020 | 242 | 0.660 |
Why?
| Rats, Wistar | 8 | 2022 | 237 | 0.650 |
Why?
| Inflammation | 3 | 2021 | 674 | 0.650 |
Why?
| Dihydropyridines | 1 | 2017 | 10 | 0.640 |
Why?
| Amlodipine | 1 | 2017 | 14 | 0.640 |
Why?
| Cerebrovascular Circulation | 1 | 2019 | 137 | 0.630 |
Why?
| Calcium Channel Blockers | 1 | 2017 | 72 | 0.610 |
Why?
| Liver Diseases | 1 | 2017 | 87 | 0.590 |
Why?
| Cognition Disorders | 1 | 2019 | 240 | 0.590 |
Why?
| Mice | 11 | 2023 | 6413 | 0.590 |
Why?
| Endothelial Cells | 6 | 2023 | 294 | 0.580 |
Why?
| Cerebral Hemorrhage | 1 | 2017 | 102 | 0.580 |
Why?
| Brain-Derived Neurotrophic Factor | 2 | 2016 | 36 | 0.580 |
Why?
| Interleukin-10 | 1 | 2017 | 107 | 0.570 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2016 | 7 | 0.560 |
Why?
| Cognition | 1 | 2019 | 348 | 0.560 |
Why?
| Mice, Inbred C57BL | 8 | 2022 | 1999 | 0.540 |
Why?
| Endothelium, Vascular | 5 | 2022 | 288 | 0.510 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2022 | 140 | 0.480 |
Why?
| Optic Nerve Injuries | 2 | 2023 | 8 | 0.450 |
Why?
| Neovascularization, Physiologic | 3 | 2022 | 72 | 0.440 |
Why?
| Brain Ischemia | 4 | 2021 | 169 | 0.440 |
Why?
| Tetrazoles | 4 | 2018 | 43 | 0.430 |
Why?
| Benzimidazoles | 4 | 2018 | 54 | 0.420 |
Why?
| Polyethylene Glycols | 2 | 2022 | 106 | 0.400 |
Why?
| Liver | 1 | 2017 | 1225 | 0.400 |
Why?
| Rats | 7 | 2022 | 3415 | 0.400 |
Why?
| Recovery of Function | 6 | 2019 | 222 | 0.370 |
Why?
| Blood-Brain Barrier | 2 | 2021 | 59 | 0.370 |
Why?
| Mice, Knockout | 7 | 2022 | 926 | 0.350 |
Why?
| Neovascularization, Pathologic | 3 | 2022 | 168 | 0.340 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2023 | 434 | 0.330 |
Why?
| Male | 14 | 2022 | 27334 | 0.310 |
Why?
| Neurons | 2 | 2021 | 486 | 0.300 |
Why?
| Oxygen | 2 | 2022 | 361 | 0.290 |
Why?
| Diabetes Mellitus | 3 | 2016 | 309 | 0.290 |
Why?
| Ornithine | 2 | 2023 | 16 | 0.280 |
Why?
| Thromboembolism | 2 | 2018 | 56 | 0.270 |
Why?
| Humans | 14 | 2024 | 54284 | 0.250 |
Why?
| Microglia | 3 | 2021 | 137 | 0.250 |
Why?
| Biphenyl Compounds | 4 | 2018 | 30 | 0.250 |
Why?
| Apoptosis | 3 | 2023 | 1300 | 0.240 |
Why?
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2021 | 21 | 0.240 |
Why?
| Ornithine Decarboxylase | 1 | 2023 | 12 | 0.240 |
Why?
| Myeloid Cells | 1 | 2023 | 37 | 0.240 |
Why?
| Retinal Ganglion Cells | 2 | 2020 | 23 | 0.230 |
Why?
| Imidazoles | 2 | 2022 | 142 | 0.230 |
Why?
| Motor Activity | 3 | 2019 | 247 | 0.220 |
Why?
| Signal Transduction | 6 | 2022 | 1753 | 0.210 |
Why?
| Blood-Retinal Barrier | 1 | 2021 | 6 | 0.210 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 37 | 0.210 |
Why?
| Copper | 1 | 2022 | 48 | 0.210 |
Why?
| Mice, Transgenic | 2 | 2021 | 656 | 0.200 |
Why?
| Optic Neuritis | 1 | 2021 | 20 | 0.200 |
Why?
| Behavior, Animal | 2 | 2019 | 200 | 0.190 |
Why?
| Cytokines | 1 | 2023 | 676 | 0.180 |
Why?
| Genes, Reporter | 1 | 2020 | 98 | 0.180 |
Why?
| Recombinant Proteins | 1 | 2021 | 569 | 0.180 |
Why?
| Recombination, Genetic | 1 | 2020 | 108 | 0.180 |
Why?
| Retinal Degeneration | 1 | 2019 | 16 | 0.180 |
Why?
| Cell Survival | 1 | 2021 | 657 | 0.180 |
Why?
| Receptors, Endothelin | 1 | 2019 | 6 | 0.180 |
Why?
| Receptors, Angiotensin | 1 | 2019 | 12 | 0.180 |
Why?
| Reactive Oxygen Species | 1 | 2022 | 491 | 0.170 |
Why?
| Face | 1 | 2019 | 66 | 0.170 |
Why?
| Nitric Oxide | 2 | 2018 | 298 | 0.170 |
Why?
| Animals, Newborn | 1 | 2020 | 396 | 0.170 |
Why?
| Multiple Sclerosis | 1 | 2019 | 72 | 0.170 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 83 | 0.170 |
Why?
| Nitric Oxide Synthase | 1 | 2018 | 102 | 0.160 |
Why?
| Forecasting | 1 | 2019 | 161 | 0.160 |
Why?
| Diagnostic Imaging | 1 | 2020 | 184 | 0.160 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2018 | 84 | 0.160 |
Why?
| Time Factors | 4 | 2019 | 3213 | 0.160 |
Why?
| Gene Deletion | 1 | 2019 | 293 | 0.160 |
Why?
| Cytoprotection | 1 | 2017 | 48 | 0.160 |
Why?
| Vascular Stiffness | 1 | 2017 | 20 | 0.160 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 75 | 0.160 |
Why?
| Calcium Signaling | 1 | 2017 | 59 | 0.150 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2017 | 96 | 0.150 |
Why?
| Administration, Intravenous | 1 | 2017 | 75 | 0.150 |
Why?
| Oxidative Stress | 3 | 2017 | 958 | 0.150 |
Why?
| Plant Extracts | 1 | 2019 | 193 | 0.150 |
Why?
| Interleukin-1beta | 1 | 2017 | 92 | 0.150 |
Why?
| Mitochondria | 1 | 2021 | 489 | 0.150 |
Why?
| Inflammation Mediators | 1 | 2017 | 128 | 0.150 |
Why?
| Tissue Plasminogen Activator | 1 | 2018 | 124 | 0.150 |
Why?
| Fibrinolytic Agents | 1 | 2018 | 139 | 0.150 |
Why?
| Biomedical Research | 1 | 2020 | 240 | 0.150 |
Why?
| Vascular Diseases | 1 | 2017 | 77 | 0.150 |
Why?
| Acute Disease | 1 | 2017 | 403 | 0.140 |
Why?
| Injections, Intraventricular | 1 | 2016 | 14 | 0.140 |
Why?
| Angiotensins | 1 | 2016 | 12 | 0.140 |
Why?
| Skin | 1 | 2019 | 469 | 0.140 |
Why?
| NF-kappa B | 1 | 2017 | 335 | 0.140 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 60 | 0.140 |
Why?
| RNA, Small Interfering | 1 | 2016 | 252 | 0.130 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 128 | 0.130 |
Why?
| Infant, Newborn | 1 | 2022 | 2907 | 0.130 |
Why?
| Alzheimer Disease | 1 | 2019 | 367 | 0.120 |
Why?
| Neuronal Plasticity | 1 | 2014 | 58 | 0.120 |
Why?
| Thioredoxins | 1 | 2014 | 30 | 0.120 |
Why?
| Rats, Sprague-Dawley | 1 | 2017 | 1663 | 0.120 |
Why?
| Female | 5 | 2022 | 28441 | 0.110 |
Why?
| Optic Nerve | 2 | 2023 | 46 | 0.110 |
Why?
| Cerebral Cortex | 1 | 2014 | 234 | 0.110 |
Why?
| Carrier Proteins | 1 | 2014 | 359 | 0.110 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2017 | 486 | 0.100 |
Why?
| Hypertension | 1 | 2016 | 564 | 0.090 |
Why?
| Cells, Cultured | 3 | 2019 | 1737 | 0.090 |
Why?
| Blood Pressure | 3 | 2018 | 587 | 0.090 |
Why?
| Cattle | 2 | 2022 | 224 | 0.090 |
Why?
| Treatment Outcome | 2 | 2017 | 5604 | 0.090 |
Why?
| Obesity | 1 | 2017 | 1202 | 0.080 |
Why?
| Random Allocation | 2 | 2018 | 312 | 0.070 |
Why?
| Nerve Crush | 1 | 2023 | 1 | 0.060 |
Why?
| Glutamates | 1 | 2023 | 22 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2015 | 230 | 0.060 |
Why?
| Cysteine | 1 | 2022 | 62 | 0.050 |
Why?
| Mitochondrial Dynamics | 1 | 2021 | 22 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 95 | 0.050 |
Why?
| HEK293 Cells | 1 | 2022 | 245 | 0.050 |
Why?
| Oxidation-Reduction | 1 | 2022 | 382 | 0.050 |
Why?
| Neuroglia | 1 | 2019 | 52 | 0.040 |
Why?
| Microvessels | 1 | 2019 | 34 | 0.040 |
Why?
| Sensory Gating | 1 | 2018 | 4 | 0.040 |
Why?
| Rats, Inbred SHR | 1 | 2018 | 33 | 0.040 |
Why?
| Cell Line | 1 | 2022 | 1153 | 0.040 |
Why?
| PPAR gamma | 1 | 2019 | 79 | 0.040 |
Why?
| Cell Hypoxia | 1 | 2018 | 87 | 0.040 |
Why?
| Amyloid beta-Peptides | 1 | 2018 | 82 | 0.040 |
Why?
| Dietary Sucrose | 1 | 2017 | 14 | 0.040 |
Why?
| Locomotion | 1 | 2018 | 83 | 0.040 |
Why?
| Up-Regulation | 1 | 2019 | 508 | 0.040 |
Why?
| Antihypertensive Agents | 1 | 2018 | 139 | 0.040 |
Why?
| Peptide Fragments | 1 | 2018 | 242 | 0.040 |
Why?
| Vasodilation | 1 | 2017 | 106 | 0.040 |
Why?
| Fibrosis | 1 | 2017 | 208 | 0.040 |
Why?
| Double-Blind Method | 1 | 2018 | 742 | 0.040 |
Why?
| Hippocampus | 1 | 2018 | 242 | 0.040 |
Why?
| Sex Factors | 1 | 2019 | 767 | 0.040 |
Why?
| Arginine | 1 | 2017 | 182 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 808 | 0.030 |
Why?
| Hydro-Lyases | 1 | 2015 | 2 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2017 | 216 | 0.030 |
Why?
| Brain Infarction | 1 | 2015 | 12 | 0.030 |
Why?
| Cerebrovascular Trauma | 1 | 2015 | 11 | 0.030 |
Why?
| Diabetes Complications | 1 | 2016 | 123 | 0.030 |
Why?
| Matrix Metalloproteinases | 1 | 2015 | 52 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 2017 | 446 | 0.030 |
Why?
| Insulin | 1 | 2017 | 510 | 0.030 |
Why?
| Middle Cerebral Artery | 1 | 2015 | 39 | 0.030 |
Why?
| Cell Communication | 1 | 2015 | 72 | 0.030 |
Why?
| Blood Glucose | 1 | 2017 | 489 | 0.030 |
Why?
| Phenotype | 1 | 2017 | 820 | 0.030 |
Why?
| Psychomotor Performance | 1 | 2015 | 156 | 0.030 |
Why?
| Muscle Strength | 1 | 2015 | 132 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2017 | 570 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 271 | 0.030 |
Why?
| Comorbidity | 1 | 2016 | 663 | 0.030 |
Why?
| Stilbenes | 1 | 2014 | 65 | 0.030 |
Why?
| Pyridines | 1 | 2015 | 137 | 0.030 |
Why?
| Epithelial Cells | 1 | 2015 | 255 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2014 | 151 | 0.030 |
Why?
| Hypoglycemic Agents | 1 | 2014 | 177 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2014 | 490 | 0.020 |
Why?
| Cell Proliferation | 1 | 2015 | 1096 | 0.020 |
Why?
|
|
Fouda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|